Abstract
Highly selective Cav2.2 voltage-gated calcium channel (VGCC) inhibitors have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Cone snail venoms provided the first drug in class with FDA approval granted in 2005 to Prialt (ω-conotoxin MVIIA, Elan) for the treatment of neuropathic pain. Since this pioneering work, major efforts underway to develop alternative small molecule inhibitors of Cav2.2 calcium channel have met with varied success. This review focuses on the properties of the Cav2.2 calcium channel in different pain states, the action of ω-conotoxins GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved Cav2.2 calcium channel therapeutics, and finally the development of small molecules for the treatment of chronic pain.
Keywords: Voltage-gated calcium channel, ωconotoxin, neuropathic pain, small molecule mimetics
Medicinal Chemistry
Title: N-type Calcium Channel Blockers: Novel Therapeutics for the Treatment of Pain
Volume: 2 Issue: 5
Author(s): C. I. Schroeder, C. J. Doering, G. W. Zamponi and R. J. Lewis
Affiliation:
Keywords: Voltage-gated calcium channel, ωconotoxin, neuropathic pain, small molecule mimetics
Abstract: Highly selective Cav2.2 voltage-gated calcium channel (VGCC) inhibitors have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Cone snail venoms provided the first drug in class with FDA approval granted in 2005 to Prialt (ω-conotoxin MVIIA, Elan) for the treatment of neuropathic pain. Since this pioneering work, major efforts underway to develop alternative small molecule inhibitors of Cav2.2 calcium channel have met with varied success. This review focuses on the properties of the Cav2.2 calcium channel in different pain states, the action of ω-conotoxins GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved Cav2.2 calcium channel therapeutics, and finally the development of small molecules for the treatment of chronic pain.
Export Options
About this article
Cite this article as:
Schroeder I. C., Doering J. C., Zamponi W. G. and Lewis J. R., N-type Calcium Channel Blockers: Novel Therapeutics for the Treatment of Pain, Medicinal Chemistry 2006; 2 (5) . https://dx.doi.org/10.2174/157340606778250216
DOI https://dx.doi.org/10.2174/157340606778250216 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Anabolic Androgenic Steroids Abuse and Liver Toxicity
Mini-Reviews in Medicinal Chemistry Hypericum perforatum, a Source of Neuroactive Lead Structures
Current Topics in Medicinal Chemistry Recent Developments in Female Hormonal Contraception
Current Women`s Health Reviews Role of Neuroimaging Modality in the Assessment of Oxidative Stress in Brain: A Comprehensive Review
CNS & Neurological Disorders - Drug Targets Pyridoxal 5-Phosphate Enzymes as Targets for Therapeutic Agents
Current Medicinal Chemistry Lysophospholipase D/Autotaxin in Lysophospholipid Biology
Current Enzyme Inhibition Increased CRMP2 Phosphorylation is Observed in Alzheimers Disease; Does this Tell us Anything About Disease Development?
Current Alzheimer Research Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets
Current Drug Targets The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling
CNS & Neurological Disorders - Drug Targets Neuroinflammation in Demyelinating Diseases: Oxidative Stress as a Modulator of Glial Cross-Talk
Current Pharmaceutical Design ACKNOWLEDGEMENT
Recent Patents on CNS Drug Discovery (Discontinued) PET Tracers for Imaging of ABC Transporters at the Blood-Brain Barrier: Principles and Strategies
Current Pharmaceutical Design The Protease of Human T-Cell Leukemia Virus Type-1 is a Potential Therapeutic Target
Current Pharmaceutical Design Pipeline Pharmacogenetics: A Novel Approach to Integrating Pharmacogenetics into Drug Development
Current Pharmaceutical Design Effects of Low Doses of Polyunsaturated Fatty Acids on the Attention Deficit/Hyperactivity Disorder of Children: A Systematic Review
Current Neuropharmacology Mesenchymal Stem Cells: A Good Candidate for Restenosis Therapy?
Current Vascular Pharmacology Neuroimaging Outcomes in Studies of Cognitive Training in Mild Cognitive Impairment and Early Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin
Current Neuropharmacology